AMENDMENTS TO THE CLAIMS

Claims 1, 8-10, 13-15 and 22 are currently pending. Please cancel claims 1, 8-10, 13-15 and 22 and insert new claims 24-32.

1.– 23. Cancelled

24. (New) A pharmaceutical composition comprising a solid amorphous dispersion of fenofibrate, or a salt or ester thereof, in a polyethylene glycol (PEG) matrix, further comprising hydroxypropylcellulose (HPMC) as an agent to inhibit crystallization.
25. (New) The composition of claim 24 wherein the solid dispersion is encapsulated in a hard gelatin capsule.
26. (New) The composition of claim 24 wherein the solid dispersion is compressed into a tablet.
27. (New) The composition of claim 24 further comprising an additive or a mixture of additives independently selected from the group consisting of pharmaceutically acceptable surfactants and antioxidants.
28. (New) A method of preparing the composition of a pharmaceutical compound comprising the steps of:
    (a) dissolving a pharmaceutical compound into an organic solvent to form a solution;
    (b) adding a polyethylene glycol (PEG) to said solution to form a mixture;
    (c) adding hydroxypropylcellulose (HPMC) to the mixture of step (b);
    (d) optionally flash evaporating said solvent;
    (e) optionally drying the resulting residue remaining after evaporation; and
    (f) optionall y grinding and sieving the solid dispersion to obtain a resultant product.
29. (New) The method of claim 28 further comprising encapsulating the solid dispersion in a hard gelatin capsule.
30. (New) The method of claim 28 further comprising compressing the solid dispersion into a tablet.
31. (New) The method of claim 28, wherein the solvent is ethanol.

32. A method for treating hyperlipidemia comprising administering an effective amount of the pharmaceutical composition of claim 1 to a mammal in need of such treatment.